Inhibitors of tyk2
US-2024425484-A1 · Dec 26, 2024 · US
Pharmacologically active compounds
US9676786B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9676786-B2 |
| Application number | US-201415107653-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 23, 2014 |
| Priority date | Dec 23, 2013 |
| Publication date | Jun 13, 2017 |
| Grant date | Jun 13, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to compounds of formula I shown below: wherein Q is as defined herein. The compounds of formula I act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or conditions in which strychnine-sensitive alpha 1-glycine receptor activity is implicated (such as, for example, chronic pain. The present invention also relates to processes for the preparation of these compounds and to pharmaceutical compositions comprising them.
First claim
Opening claim text (preview).
The invention claimed is: 1. (4-(hydroxy)-3,5-diisopropylphenyl)(morpholino)methanone or a pharmaceutically acceptable salt or solvate thereof. 2. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof, in admixture with a pharmaceutically acceptable diluent or carrier. 3. A method of treating chronic pain or inducing anaesthesia in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof.
Assignees
Inventors
Classifications
not condensed with other rings · CPC title
from aromatic carboxylic acids · CPC title
Drugs for disorders of the nervous system · CPC title
having no double bonds between ring members or between ring members and non-ring members · CPC title
having no double bonds between ring members or between ring members and non-ring members · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9676786B2 cover?
- The present invention relates to compounds of formula I shown below: wherein Q is as defined herein. The compounds of formula I act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or co…
- Who is the assignee on this patent?
- Univ Liverpool
- What technology area does this patent fall under?
- Primary CPC classification C07D491/107. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).